| 期 |
栏目 |
标题 |
文件 |
| 卷 26, 编号 4 (2019) |
Articles |
Potential drug interactions of oral hypoglycemic drugs that increase the risk of hypoglycemia |
|
| 卷 26, 编号 14 (2019) |
Articles |
Hypoglycemic drugs and drug-induced heart failure |
|
| 卷 26, 编号 14 (2019) |
Articles |
Drug-induced hyperthyroidism |
|
| 卷 27, 编号 2 (2020) |
Articles |
Medicines associated with the development of drug-induced constipation |
|
| 卷 27, 编号 4 (2020) |
Articles |
Individual drugs associated with overweight inducing |
|
| 卷 27, 编号 4 (2020) |
Articles |
Medicines associated with the development of osteoporosis |
|
| 卷 27, 编号 3 (2020) |
Articles |
Approaches to choosing a direct oral anticoagulant in the treatment of polymorbid patients with atrial fibrillation |
|
| 卷 27, 编号 3 (2020) |
Articles |
The benefits of fixed combinations for the treatment of arterial hypertension in women with menopausal disorders: focus on Gipotef |
|
| 卷 27, 编号 5 (2020) |
Articles |
Drug-induced diseases: epidemiology and urgency of the problem |
|
| 卷 27, 编号 6 (2020) |
Articles |
Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance |
|
| 卷 28, 编号 3 (2021) |
Articles |
The relationship of cardiovascular disease with increased intestinal permeability: results from scientific and controlled clinical trials. Focus on the potential of rebamipide |
|
| 卷 28, 编号 3 (2021) |
Articles |
The choice of antianginal therapy for polymordib patients with coronary artery disease and type 2 diabetes mellitus: the benefits of trimetazidine |
|
| 卷 28, 编号 5 (2021) |
Articles |
Tobacco smoking as a risk factor for the development of drug-induced diseases |
|
| 卷 28, 编号 11 (2021) |
Articles |
Medication errors as risk factor for drug-induced diseases |
|
| 卷 28, 编号 12 (2021) |
Articles |
Risk factors of drug-induced diseases. Part 2. Comorbid diseases and lifestyle factors |
|
| 卷 29, 编号 1 (2022) |
Articles |
Risk factors of drug-induced diseases. Part 3. Drug-drug and drug-food interactions |
|
| 卷 29, 编号 3 (2022) |
Articles |
Risk factors of drug-induced diseases. Part 4. Medication errors and patient adherence |
|
| 卷 29, 编号 11/12 (2022) |
Articles |
Drugs, the use of which is associated with the development of drug-induced kidney stone disease. Part 2 |
|
| 卷 29, 编号 13 (2022) |
Articles |
Controversial and unresolved aspects of drug-induced hemorrhagic stroke: focus on selective serotonin reuptake inhibitors, non-steroidal anti-inflammatory drugs and statins |
|
| 卷 29, 编号 13 (2022) |
Articles |
Structure of prescription of gastroprotective drugs in patients receiving direct oral anticoagulants: results of a multicenter cross-sectional pharmacoepidemiological study |
|
| 卷 30, 编号 14 (2023) |
Cardiology |
On the issue of improving the safety of antithrombotic therapy in patients with atrial fibrillation and coronary heart disease receiving antithrombotic therapy |
|
| 卷 31, 编号 1 (2024) |
Cardiology |
On the possible relationship between the presence of polymorphic variants of CYP3A4/5 cytochrome genes, their metabolic activity with rivaroxaban pharmacokinetics and the development of bleeding in patients with non-valvular atrial fibrillation and chronic kidney disease |
|
| 卷 31, 编号 1 (2024) |
Cardiology |
Arterial hypertension and cognitive impairment in elderly and senile patients: basic approaches to patient management |
|
| 卷 31, 编号 1 (2024) |
Cardiology |
State of cognitive functions in patients with various forms of atrial fibrillation |
|
